CLOs on the Move

Aclaris Therapeutics

www.aclaristx.com

 
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Matthew Rothman
general counsel and corporate secretary Profile
Spencer Brown
Senior Vice President of Legal Affairs and Compliance Officer Profile
Kamil Ali-Jackson
Co-Founder, Chief Legal Officer, Chief Compliance Officer and Corporate Secretary Profile

Similar Companies

Eli Lilly

Lilly makes medicines that help people live longer, healthier, more active lives. We were founded by Eli Lilly in 1876, and are now the 10th largest pharmaceutical company in the world. We have steadfastly remained independent, but not isolated. Across the globe, Lilly has developed productive alliances and partnerships that advance our capacity to develop innovative medicines at lower costs. Lilly is consistently ranked as one of the best companies in the world to work for, and generations of Lilly employees have sustained a culture that values excellence, integrity, and respect for people. We make medicines that help people live longer, healthier, more active lives.

Tiba Medical

Tiba Medical is a Portland, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synthonics

Synthonics is a Blacksburg, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bayer Healthcare

The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subsidiary of Bayer AG, is one of the world's leading, innovative companies in the healthcare and medical

Milestone Pharmaceuticals

Milestone was founded in 2005 with the underlying concept to base its drug development programs on clinically validated mechanisms of action in order to mitigate as much drug development risk as possible. The company has raised a total of $34 million in venture capital financing since 2006. At its founding, the company assembled a panel of leading pharmaceutical R&D executives (“drug hunters”) each with an average of 30 years experience in drug development. The drug hunters proposed NCE projects based on clinically proven science to form the basis of Milestone’s drug development programs. Milestone has a seasoned management team with experience in cardiovascular diseases, drug development and business start-ups as well as world-class advisory boards of key opinion leaders with significant expertise in cardiology, regulatory affairs, as well as formulation and drug development.